A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849Phase 3Recruiting
- Lead sponsor
- Incyte Corporation (Industry)
- Enrollment
- 700 (estimated)
- Start date
- 5 Mar 2026
- Primary completion
- 29 Dec 2028 (estimated)
- Study completion
- 28 Sep 2029
- Last update posted
- 30 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- INCA33890 Drug
- Placebo Drug
- Bevacizumab Drug
- FOLFOX Drug
Conditions and primary outcome
- CRC (Colorectal Cancer)
Primary outcome
Progression-Free Survival (PFS) (Up to 3 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07284849.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07284849 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.